Nervenheilkunde 2017; 36(09): 747-750
DOI: 10.1055/s-0038-1627522
Universitätsklinikum Ulm
Schattauer GmbH

Cardiac arrhythmias related to psychiatric medication

A brief reviewKardiale Arrhythmien im Zusammenhang mit PharmakotherapieEine kurze Übersicht
M. Elsayed
1   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
R. W. Freudenmann
1   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
C. Schönfeldt-Lecuona
1   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
B. J. Connemann
1   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
M. Gahr
1   Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm
› Author Affiliations
Further Information

Publication History

eingegangen am: 02 July 2017

angenommen am: 24 July 2017

Publication Date:
20 January 2018 (online)


This narrative review summarizes current available information about cardiac arrhythmias (QT prolongation, Torsade de pointes Tachycardia [TdP], sudden cardiac death) associated with psychiatric medication. Among the most commonly used antipsychotics, amisulpride and ziprasidone are most frequently associated with TdP. Treatment with some antidepressants (SSRIs, tricyclic antidepressants) is associated with a 5- to 6-fold increase in the incidence of out-of-hospital cardiac arrest. Lithium is associated with bradycardia, T-wave changes and AV-block; anxiolytics of the benzodiazepine group do usually not have cardiac side effects. The combination of multiple drugs (including medications from general medicine) that prolong the QT interval has a particularly high cardiac risk.


Diese narrative Übersichtsarbeit fasst das Wissen über kardiale Arrhythmien (z. B. QT-Zeit-Verlängerung, Torsade de pointes Tachykardie TdP, plötzliche Herztod) unter Psychopharmaka zusammen. Unter den gebräuchlichsten Antipsychotika sind Amisulprid und Ziprasidon am häufigsten mit TdP assoziiert. Die Behandlung mit einigen Antidepressiva (SSRIs, trizyklische Antidepressiva) ist mit einer 5- bis 6-fachen Erhöhung der Inzidenz von ambulanten Herzstillständen assoziiert. Lithiumtherapie ist mit Bradykardie, T-Wellen-Veränderungen und AV-Block assoziiert. Anxiolytika vom Typ der Benzodiazepine zeigen meist keine kardialen Nebenwirkungen. Besonders kardial risikoreich hingegen ist die Kombination von mehreren Medikamenten (auch Nichtpsychopharmaka), die die QT-Zeit verlängern.

  • References

  • 1 Jakovljević M. How to increase treatment effectiveness and efficacy in psychiatry: Creative Psychopharmacotherapy Part 2: Creating Favorable Treatment Context and Fostering Patients’ Creativity. Psychiatr Danub 2013; 25 (03) 274-9.
  • 2 Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J. et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J 2014; 35 (20) 1306-15.
  • 3 Elbe D, Savage R. How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. J Can Acad Child Adolesc Psychiatry 2010; 19 (01) 40-5.
  • 4 Marano G, Traversi G, Romagnoli E, Catalano V, Lotrionte M, Abbate A. et al. Cardiologic side effects of psychotropic drugs. J Geriatr Cardiol 2011; 08 (04) 243-53.
  • 5 Chong SA, Mythily Mahendran R. Cardiac effects of psychotropic drugs. Ann Acad Med Singapore 2001; 30 (06) 625-31.
  • 6 Timour Q, Frassati D, Descotes J, Chevalier P, Christé G, Chahine M. Sudden death of cardiac origin and psychotropic drugs. Front Pharmacol 2012; 03: 76.
  • 7 Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-7.
  • 8 Atypical antipsychotics, schizophrenia, and cardiovascular risk: What family physicians need to know. BC Medical Journal. 2017 Jul 9.
  • 9 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB. et al. Heart disease and stroke statistics - 2013 Update: A report from the American Heart Association. Circulation 2013; 127 (01) e6-245.
  • 10 Shah AA. et al. QTc prolongation with antipsychotics. J Psychiatr Pract 2014; 20 (03) 196-206.
  • 11 Davis AS. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. 2017 Jul 20;
  • 12 Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: How should institutions respond?. J Hosp Med 2010; 05 (04) E8-16.
  • 13 Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23 (01) 58-77.
  • 14 Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C. et al. The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47 (02) 219-33.
  • 15 Carmeliet E. Mechanisms and control of repolarization. Eur Heart J 1993; 14 (suppl H): 3-13.
  • 16 Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG. et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999; 99 (04) 518-28.
  • 17 Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B. et al. Drug-induced long QT syndrome in injection drug users receiving methadone. Arch Intern Med 2006; 166 (12) 1280.
  • 18 Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Annunziato L. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br J Pharmacol 2000; 131 (06) 1081-8.
  • 19 Stoudemire A, Moran MG, Fogel BS. et al. Psychotropic drug use in the medically ill. Part II. Psychosomatics 1991; 32 (01) 34-46.
  • 20 Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382 9896 951-62.
  • 21 Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000; 25 (02) 154-60.
  • 22 Vieweg WVR, Hasnain M, Howland RH, Clausen T, Koneru JN, Kogut C. et al. Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem. Ther Adv Psychopharmacol 2013; 03 (04) 219-32.
  • 23 Poluzzi E, Raschi E, Moretti U, De Ponti F. Druginduced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18 (06) 512-8.
  • 24 Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010; 05 (01) 97-104.
  • 25 Gintant G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 2011; 129 (02) 109-19.
  • 26 Alvarez W, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003; 23 (06) 754-71.
  • 27 Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994; 55 Suppl A: 83-7-9, 98-100.
  • 28 Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2010; 04: 93-101.
  • 29 Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C. et al. Antidepressant use and risk of out-of-hospital cardiac arrest: A nationwide case-time-control study. Clin Pharmacol Ther 2012; 92 (01) 72-9.
  • 30 Empana JP, Jouven X, Lemaitre RN, Sotoodehnia N, Rea T, Raghunathan TE. et al. Clinical depression and risk of out-of-hospital cardiac arrest. Arch Intern Med 2006; 166 (02) 195.
  • 31 Bruggisser, Bravo R. Bodmer Medikamenten-assoziiertes Long-QT-Syndrom. Praxis 2009; 98 (24) 1409-15.
  • 32 Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E. et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 04 (01) 1.
  • 33 Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008; 04 (02) 101-5.
  • 34 Amdisen A. Serum concentration and clinical supervision in monitoring of lithium treatment. Ther Drug Monit 1980; 02 (01) 73-83.
  • 35 Hsu C-H, Liu P-Y, Chen J-H, Yeh T-L, Tsai H-Y, Lin L-J. Electrocardiographic abnormalities as predictors for over-range lithium levels. Cardiology 2005; 103 (02) 101-6.
  • 36 Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355 9209 1048-52.
  • 37 Mamiya K, Sadanaga T, Sekita A, Nabeyama Y, Yao H, Yukawa E. Lithium concentration correlates with QTc in patients with psychosis. J Electrocardiol 2005; 38 (02) 148-51.
  • 38 Talati SN, Aslam AF, Vasavada B. Sinus node dysfunction in association with chronic lithium therapy: A case report and review of literature. Am J Ther 2009; 16 (03) 274-8.
  • 39 Katz DF, Sun J, Khatri V, Kao D, Bucher-Bartelson B, Traut C. et al. QTc interval screening in an opioid treatment program. Am J Cardiol 2011; 112 (07) 1013-8.
  • 40 Wedam EF. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167 (22) 2469.